Sunshine Biopharma Inc. - Warrant (NQ:SBFMW)

0.0252 +0.0001 (+0.40%)

Delayed Quote Updated: 10:25 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Warrant

Sunshine Biopharma Q2 Report Reveals Approximately 1,940% Increase In Cash & Cash Equivalents And 80% Decrease In Net Loss Within 6 Months ↗

August 08, 2022

Sunshine Biopharma, Inc. (NASDAQ: SBFM) (NASDAQ: SBFMW) announced that it has filed its 2022 second-quarter report with the Securities and Exchange Commission.

Via Benzinga

Sunshine Biopharma Reveals Potential Intellectual Property Position In Connection With Ongoing mRNA-As-Therapeutics-Agents Research ↗

April 26, 2022

Photo credit: Patent application by Nick Youngson CC BY-SA 3.0

Via Benzinga

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells ↗

April 25, 2022

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc.

Via Benzinga

Sunshine Biopharma Sees Potential Multi-Billion Dollar Global Market Opportunity As Research Findings Reveal Effectiveness Against Multidrug-Resistant Cancer Cells ↗

April 06, 2022

Photo by Angiola Harry on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Sunshine Biopharma, Inc. Announces Pricing of $8 Million Private Placement Priced At-the-Market ↗

March 14, 2022

Photo by Scott Graham on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)

February 17, 2022

NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)...

From Aegis Capital Corp.

Via AccessWire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.